Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam extension in Alzheimer's disease
NCT05352763Phase 2
Key facts
- Status
- Terminated
- Start
- May 2022
- Primary completion
- Dec 2024
- Countries
- 2
- Sponsor
- Cassava Sciences
- Modality
- Small Molecules
- Drugs
- simufilam
- Conditions
- Alzheimer's disease (AD)
01
Overview
Phase 2, open-label, single-arm trial of simufilam in Alzheimer's disease (AD), sponsored by Cassava Sciences. Primary endpoint: Adverse Event Monitoring at 96 weeks. Started May 2022; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Simufilam 100 mg
Simufilam 100 mg oral tablets, twice daily
03
Who it enrols
Patients with mild-to-moderate Alzheimer's disease who completed the Phase 2 study PTI-125-04 (NCT04388254) or completed Week 96 in this study (PTI-125-09).
04
Endpoints
Primary
Adverse Event Monitoring
Beyond the preview
Go deeper on NCT05352763.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352763.